CADL · CIK 0001841387 · operating
Candel Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies based on herpes simplex virus (HSV) for solid tumor cancers. The company's lead candidate, CAN-2409, is in Phase III trials for prostate cancer and Phase II trials for pancreatic cancer and non-small cell lung cancer. A second program, CAN-3110, is in Phase Ib development for recurrent high-grade glioma. These candidates are generated through the company's enLIGHTEN Discovery Platform, a systematic discovery approach that uses human biology and advanced analytics to identify viral immunotherapy candidates.
The company has no approved products or commercial revenue streams, as all programs remain in clinical development. Operating expenses are primarily directed toward clinical trial conduct and research activities. Candel Therapeutics maintains a lean operational structure with 38 full-time employees and is based in Needham, Massachusetts. The company was incorporated in Delaware in 2003 under the name Advantagene, Inc., and assumed its current name in November 2020. Candel trades on the Nasdaq exchange and has a market capitalization of approximately $0.3 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.74 | $-1.74 | -32.8% | |
| 2023 | $-1.31 | $-1.31 | -101.5% | |
| 2022 | $-0.65 | $-0.65 | — | |
| 2021 | — | — | — |